LEKSELL GAMMA KNIFE® PERFEXION™ SETTING NEW STANDARDS FOR FAST, EFFECTIVE, PRECISE RADIOSURGERY TREATMENTS

LEKSELL GAMMA KNIFE® PERFEXION™ SETTING NEW STANDARDS FOR FAST, EFFECTIVE,
PRECISE RADIOSURGERY TREATMENTS

PRESS RELEASE	
Stockholm, Sweden, June 18, 2007

One year after the first Leksell Gamma Knife® Perfexion™ treatment was performed
in Marseille, France, the revolutionary radiosurgery system is exceeding
expectations and delivering fast, effective, precise radiosurgery treatments and
to date, has treated more than 300 patients. Physicians now have an
unprecedented ability to develop and deliver complex treatment plans for
patients with metastatic brain tumors.

In June, Washington Hospital Healthcare System, Freemont, CA, became the first
U.S. site to treat patients with Leksell Gamma Knife Perfexion. “We treated
three patients the first day, and our clinical team was astounded by the ease
and speed of the treatments, as well as the ability to conform the dose to the
target at a sub-millimeter level,” said David Larson, M.D., Ph.D., F.A.C.R.,
radiation oncologist and co-director of the Gamma Knife program at Washington
Hospital. 

“The patients we treated had very complex targets or multiple brain metastases,
but the treatments only took one to two hours each,” said Larson. “In the past,
equally conformal treatments would have required well over five hours, even with
the most recent Gamma Knife model, which until now, was the fastest and most
efficient radiosurgery device available.” 

Gamma Knife surgery has become the world's most widely used radiosurgery
treatment for brain disorders due to its extraordinary accuracy, reduction of
excess radiation dose to the body and extensive history and clinical
documentation. Unlike other systems designed to treat the whole body, Leksell
Gamma Knife is specifically designed to optimize treatment to the head - a fact
appreciated by neurosurgeons and patients alike.

Developed in conjunction with leading neurosurgeons, Leksell Gamma Knife
Perfexion is:

• Precise - thousands of radiation beams converge with a level of accuracy more
than 0.5mm, about the thickness of a strand of hair, leaving nearby healthy
tissue undamaged.

• Proven - With almost 500,000 patients treated worldwide, and thousands of
peer-reviewed scientific articles, the system has unmatched clinical experience.

• Safe - Unwanted radiation dose to the body is up to 100 times less than that
of competing technologies.

Gamma Knife surgery is the only stereotactic radiosurgery system specifically
cleared by the FDA for treating metastatic brain tumors. In comparison to linac
radiosurgery, peer-reviewed articles and publications prove the tremendous
benefit of Gamma Knife surgery for significantly better local tumor control.(1) 







(1) Single dose radiosurgical treatment of recurrent previously irradiated
primary brain tumors and brain metastases: final report of RTOG protocol 90-05
Journal:  Int J Radiat Oncol Biol Phys , Vol: 47, No. 2: pages 291-8. ,  May 1,
2000 Authors:  Shaw E; Scott C; Souhami L; Dinapoli R; Kline R; Loeffler J;
Farnan N 

Related Links:

www.Elekta.com
www.BrainTumorTreatment.org
www.irsa.org


******

For further information, please contact:

Media inquiries: Michelle Lee, PR and Advertising Manager, Tel: +1 770-670-2447,

e-mail: michelle.lee@elekta.com

Investor inquiries: Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.